{"ok":true,"entity":{"id":"sanofi","name":"Sanofi","entityType":"company","officialName":"Sanofi S.A.","canonicalName":"Sanofi","displayName":"Sanofi","category":"大手製薬企業","shortDescription":"フランス・パリに本社を置くヘルスケア企業。ワクチン（Sanofi Vaccines）、免疫疾患、希少疾患、神経疾患を重点領域とし、Regeneronと共同開発したDupixent（dupilumab）を最大の成長ドライバーとする。コンシューマーヘルスケア事業Opellaの分離を進め、イノベーティブ医薬品への集中を強めている。","primaryCluster":"pharmaceuticals","parentEntity":null,"verificationStatus":"draft","website":"https://www.sanofi.com","updatedAt":"2026-08-06T01:18:46.240Z","secondaryClusters":[],"alias":[],"searchKeywords":["ワクチン","免疫疾患","希少疾患","Dupixent"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-06-001","P-04-002"]}